Non-Small-Cell Lung Carcinoma Archives | MSD Oncology Clinical Trials

Coformulation of Pembrolizumab/Vibostolimab Versus Pembrolizumab Monotherapy for Programmed Cell Death 1 Ligand 1 Positive Metastatic Non-Small Cell Lung Cancer

March 7, 2022

The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS) in participants with programmed cell death 1 ligand 1 (PD-L1) tumor proportion

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer

March 7, 2022

By Support_Clique

This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in participants with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who

Condition: Non-Small-Cell Lung Carcinoma

Condition: Non-Small-Cell Lung Carcinoma

Coformulation of Pembrolizumab/Vibostolimab Versus Pembrolizumab Monotherapy for Programmed Cell Death 1 Ligand 1 Positive Metastatic Non-Small Cell Lung Cancer

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer